Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Levine, E. Bates, L. Mauri, J. Bittl, R. Mehran, R. Brindis, D. Mukherjee, S. Fihn, L. Newby, L. Fleisher, P. O'Gara, C. Granger, M. Sabatine, R. Lange, Peter Smith, M. Mack, Sidney Smith, L. Curtis, S. Pressler (2016)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Journal of the American College of Cardiology, 68 10
A. Liberati, D. Altman, J. Tetzlaff, C. Mulrow, P. Gøtzsche, J. Ioannidis, M. Clarke, P. Devereaux, J. Kleijnen, D. Moher (2009)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLoS Medicine, 6
M. Valgimigli, H. Bueno, R. Byrne, J. Collet, F. Costa, A. Jeppsson, P. Jüni, A. Kastrati, P. Kolh, L. Mauri, G. Montalescot, F. Neumann, M. Petricevic, M. Roffi, P. Steg, S. Windecker, J. Zamorano, G. Levine (2018)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 53 1
J. Hahn, Y. Song, J. Oh, W. Chun, Yong Park, W. Jang, E. Im, J. Jeong, B. Cho, S. Oh, K. Yun, D. Cho, Jong-Young Lee, Young‐Youp Koh, J. Bae, Jaewoong Choi, Wang-Soo Lee, H. Yoon, S. Lee, Jang-hyun Cho, W. Choi, S. Rha, J. Lee, T. Park, Jeong Yang, Jin‐Ho Choi, S. Choi, Sang Lee, H. Gwon (2019)
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.JAMA, 321 24
C. Cannon, R. Harrington, S. James, D. Ardissino, R. Becker, H. Emanuelsson, S. Husted, H. Katus, M. Keltai, N. Khurmi, F. Kontny, B. Lewis, P. Steg, R. Storey, D. Wojdyla, L. Wallentin (2010)
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyThe Lancet, 375
Choongki Kim, Sung‐Jin Hong, D. Shin, Byeong‐Keuk Kim, C. Ahn, Jung‐Sun Kim, Y. Ko, D. Choi, M. Hong, Y. Jang (2019)
Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.American heart journal, 212
Goutham Rao, F. Lopez‐Jimenez, J. Boyd, F. D'Amico, N. Durant, M. Hlatky, G. Howard, Katherine Kirley, Christopher Masi, T. Powell-Wiley, A. Solomonides, C. West, J. Wessel (2017)
Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association.Circulation, 136 10
GN Levin, ER Bates, JA Bittl (2016)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac SurgeryCirculation, 134
G. Luca, S. Damen, C. Camaro, E. Benit, M. Verdoia, S. Rasoul, H. Liew, J. Polad, W. Ahmad, R. Zambahari, S. Postma, Elvin Kedhi, H. Suryapranata (2019)
Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
P. Armstrong, P. Leadbeater, M. Chan, N. Kirkby, Joseph Jakubowski, J. Mitchell, Timothy Warner (2011)
In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregationJournal of Thrombosis and Haemostasis, 9
(2019)
Ticagrelor with or without aspirin in high-risk Abbreviated DAPT Followed by P2Y12 Inhibitor Monotherapy Post PCI patients after PCI
T. Park, Y. Song, H. Gwag, W. Jang, Jeong Yang, J. Hahn, Seung‐Hyuk Choi, Jin‐Ho Choi, Sang Lee, H. Gwon (2014)
ASPIRIN VERSUS CLOPIDOGREL FOLLOWING DUAL ANTIPLATELET THERAPY ON THE ERA OF DRUG-ELUTING STENTSJournal of the American College of Cardiology, 63
A. Liberati, D. Altman, J. Tetzlaff, C. Mulrow, P. Gøtzsche, J. Ioannidis, M. Clarke, P. Devereaux, J. Kleijnen, D. Moher (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationThe BMJ, 339
Hirotoshi Watanabe, T. Domei, T. Morimoto, Masahiro Natsuaki, H. Shiomi, T. Toyota, M. Ohya, S. Suwa, K. Takagi, M. Nanasato, Yoshiki Hata, Masahiro Yagi, N. Suematsu, Takafumi Yokomatsu, I. Takamisawa, M. Doi, T. Noda, H. Okayama, Yoshitane Seino, T. Tada, H. Sakamoto, K. Hibi, M. Abe, K. Kawai, K. Nakao, K. Ando, K. Tanabe, Y. Ikari, K. Hanaoka, Y. Morino, K. Kozuma, K. Kadota, Y. Furukawa, Y. Nakagawa, Takeshi Kimura (2019)
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.JAMA, 321 24
P Vranckx, M Valgimigli, P Jüni, C Hamm, PG Steg, D Heg (2018)
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentreLancet, 392
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
R. Mehran, U. Baber, Samin Sharma, D. Cohen, D. Angiolillo, C. Briguori, Jin Cha, T. Collier, G. Dangas, D. Dudek, V. Džavík, J. Escaned, R. Gil, P. Gurbel, C. Hamm, T. Henry, K. Huber, A. Kastrati, U. Kaul, R. Kornowski, M. Krucoff, V. Kunadian, S. Marx, S. Mehta, D. Moliterno, E. Ohman, K. Oldroyd, G. Sardella, S. Sartori, R. Shlofmitz, P. Steg, G. Weisz, B. Witzenbichler, Ya‐Ling Han, S. Pocock, C. Gibson (2019)
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.The New England journal of medicine
B. Lagerqvist, S. James, U. Stenestrand, J. Lindbäck, T. Nilsson, L. Wallentin (2007)
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.The New England journal of medicine, 356 10
T. Palmerini, U. Benedetto, L. Bacchi-Reggiani, D. Riva, G. Biondi‐Zoccai, F. Feres, A. Abizaid, M. Hong, Byeong‐Keuk Kim, Y. Jang, Hyo‐Soo Kim, K. Park, P. Généreux, Deepak Bhatt, Carlotta Orlandi, S. Servi, M. Petrou, C. Rapezzi, G. Stone (2015)
Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trialsThe Lancet, 385
M Valgimigli, H Bueno, RA Byrne, J-P Collet, F Costa, A Jeppsson (2017)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the EuropeanEur Heart J, 39
H Watanabe, T Domei, T Morimoto, M Natsuaki, H Shiomi, T Toyota (2019)
Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial effect of 1- vs 12-month dual antiplatelet TJAMA, 321
J-Y Hahn, YB Song, J-H Oh, WJ Chun, YH Park, WJ Jang (2019)
Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial P2Y12 monotherapy vs DAPT and cardiovascular events in patientJAMA, 321
L. Traby, M. Kollars, A. Kaider, S. Eichinger, M. Wolzt, P. Kyrle (2016)
Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjectsJournal of Thrombosis and Haemostasis, 14
L. Mauri, D. Kereiakes, Robert Yeh, Priscilla Driscoll-Shempp, D. Cutlip, P. Steg, Sharon-Lise Normand, Eugene, Braunwald, S. Wiviott, David Cohen, David Holmes, Mitchell Krucoff, J. Hermiller, H. Dauerman, I. Daniel, Simon, D. Kandzari, Kirk Garratt, David Lee, Thomas Pow, Peter Lee, Michael Rinaldi, Joseph Massaro (2014)
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.The New England journal of medicine, 371 23
IntroductionAn increased incidence of stent thrombosis after implantation of first-generation drug-eluting stents led to a recommendation of dual antiplatelet therapy (DAPT) for 12 months after the procedure. However, given the use of second-generation and newer drug-eluting stents, this recommendation needs to be revisited. Several randomized controlled trials (RCTs) have studied an abbreviated DAPT regimen of ≤ 3 months followed by P2Y12 inhibitor monotherapy, and results have been conflicting.ObjectiveWe performed a systematic review with meta-analysis of RCTs of abbreviated DAPT for ≤ 3 months followed by P2Y12 monotherapy compared with 12 months of DAPT.MethodsWe performed a systematic search of the MEDLINE/PubMed, Cochrane, and DARE (Database of Abstracts of Reviews of Effects) databases for eligible RCTs. Quantitative analysis was performed based on the intention-to-treat principle. We used the Mantel–Haenszel method with a random-effects model to calculate relative risks (RRs) with 95% confidence intervals (CIs).ResultsThe final analysis included four RCTs. We found no difference in the risk of all-cause mortality (RR 0.90; 95% CI 0.77–1.05; p = 0.18; I2 = 0%; χ2p = 0.58), myocardial infarction (RR 0.99; 95% CI 0.86–1.15; p = 0.85; I2 = 0%; χ2p = 0.70), stroke (RR 1.14; 95% CI 0.65–1.98; p = 0.65; I2 = 59%; χ2p = 0.06), or stent thrombosis (RR 0.98; 95% CI 0.73–1.33; p = 0.90; I2 = 0%; χ2p = 0.48). Additionally, there was no difference in the risk for major bleeding, defined as BARC (Bleeding Academic Research Consortium) type 3 or 5, between the two groups (RR 0.62; 95% CI 0.37–1.05; p = 0.07; I2 = 79%; χ2p < 0.05).ConclusionAbbreviated DAPT followed by P2Y12 monotherapy resulted in a similar risk of re-ischemic clinical outcomes post percutaneous coronary intervention as compared with the standard 12-month DAPT regimen. The risk of major bleeding (BARC type 3 or 5) also remained similar between the two groups. However, as trials have reported benefits with abbreviated DAPT followed by P2Y12 monotherapy in terms of combined endpoints and all bleeding (BARC type 2–5), additional research is needed.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 30, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.